Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J01D

Fetcroja(cefiderocol sulfate tosilate)

Gram-Negative Bacterial Infections

Marketing Authorisation Holder: Shionogi B.V.

EMA Authorisation: 23/04/2020

INN: cefiderocol

Indication

Fetcroja is indicated for the treatment of infections   due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Fetcroja — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.